Sirona Biochem Corp. (SRBCF) 0.1160 $SRBCF
Sirona Biochem Launches Anti-Aging Preclinical Studies
Marketwire - Mon Sep 22, 6:45AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) launches the next stage of development for its anti-aging compound library. With recent funding from Bpifrance (the French Public Investment Bank) and the district of Haute Normandie, Sirona Biochem's subsidiary TFChem (France) moves into the next phase of the agreement with the French laboratory Biogalenys.
Sirona Biochem Announces Positive Results of PK Study for Type 2 Diabetes
Marketwire - Wed Sep 03, 3:30PM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB) today announced that Wanbang Biopharmaceuticals has successfully completed another study in the pre-clinical validation of its anti-diabetic SGLT2 Inhibitor, SBM-TFC-039, for the treatment of Type 2 diabetes.
Sirona Biochem Launches Global Awareness Campaign With Cousteau Ambassadors' Video
Marketwire - Thu Aug 21, 2:00AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) launches global awareness campaign with ambassadors' video produced by the team of Jean-Michel Cousteau and Fabien Cousteau to represent their support of the glycoprotein project.
Sirona Subsidiary, TFChem, Receives CDN$1.2 Million for Anti-Aging Project
Marketwire - Tue Aug 12, 6:45AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB), (the "Company"
announced that its French subsidiary, TFChem, has received confirmation for funding of CDN$1.2 million from Bpifrance (the French Public Investment Bank) and the district of Haute Normandie in the form of a no-interest loan. The funds will be used to advance the organization's anti-aging project.
Sirona Biochem Announces Successful Synthesis of Anti-Inflammatory Compound for Bloom Burton & Co. Joint Venture
Marketwire - Thu Jul 31, 6:45AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB), (the "Company" announces the achievement of the first batch of compound in the joint venture with Bloom Burton & Co. ("Bloom Burton" Compounds developed within the framework of the JV will be entering development in the areas of rare inflammatory and infectious diseases.
Sirona Arranges Convertible Loans
Marketwire - Tue Jul 29, 4:48PM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB), (the "Company" announces that is has entered into convertible loan agreements with arm's length parties (the "Lenders" for the purposes of renewing current outstanding loans in the total amount of $670,000. The original loans were taken out in late 2012 and became due this quarter.
Sirona Biochem Announces Successful Completion of Two First Line Studies by Wanbang Biopharmaceuticals
Marketwire - Wed Jul 23, 6:45AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM)(OTCQX: SRBCF)(FRANKFURT: ZSB) (the "Company" today announced that Wanbang Biopharmaceuticals has completed two pre-clinical efficacy studies of its SGLT2 inhibitor SBM-TFC-039. The studies independently confirm that SBM-TFC-039 increased Urinary Glucose Excretion and improved Oral Glucose Tolerance in normal SD rats. The results were consistent with those previously completed by Sirona Biochem.
Sirona Announces Shares for Services Agreement
Marketwire - Tue Jul 22, 11:27AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB), (the "Company" is pleased to announce that it has entered into a business consulting agreement (the "Agreement" with PRC Partners Ltd. of Hong Kong ("PRC" , for a six month term commencing July 15, 2014.
Sirona Biochem Corporation - CEO Letter to Shareholders
Marketwire - Mon Jul 21, 9:27AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB) today provided a business update.
Sirona Announces Resignation of Neil Belenkie
Marketwire - Mon Jun 23, 4:00PM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB) (the "Company" announces that Neil Belenkie has resigned as Chief Executive Officer of the Company. Neil has agreed to stay on with the company to assist in the transition until July 18, 2014. The Company thanks Mr. Belenkie for his hard work over the past 2 years and wishes him well in his future endeavors.
Sirona Biochem Announces Patent for Anti-Aging Family of Compounds
Marketwire - Tue Apr 01, 6:45AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM.V) (OTCQX: SRBCF) (FRANKFURT: ZSB) is pleased to announce that a new patent application has been deposited by its subsidiary TFChem for a second generation of glycoprotein compounds. The first target marketplace for this technology will be anti-aging cosmetics. Future applications may include consumer packaged goods and prescription pharmaceuticals.
Sirona Biochem Launches Anti-Aging Preclinical Studies
Marketwire - Mon Sep 22, 6:45AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) launches the next stage of development for its anti-aging compound library. With recent funding from Bpifrance (the French Public Investment Bank) and the district of Haute Normandie, Sirona Biochem's subsidiary TFChem (France) moves into the next phase of the agreement with the French laboratory Biogalenys.
Sirona Biochem Announces Positive Results of PK Study for Type 2 Diabetes
Marketwire - Wed Sep 03, 3:30PM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB) today announced that Wanbang Biopharmaceuticals has successfully completed another study in the pre-clinical validation of its anti-diabetic SGLT2 Inhibitor, SBM-TFC-039, for the treatment of Type 2 diabetes.
Sirona Biochem Launches Global Awareness Campaign With Cousteau Ambassadors' Video
Marketwire - Thu Aug 21, 2:00AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) launches global awareness campaign with ambassadors' video produced by the team of Jean-Michel Cousteau and Fabien Cousteau to represent their support of the glycoprotein project.
Sirona Subsidiary, TFChem, Receives CDN$1.2 Million for Anti-Aging Project
Marketwire - Tue Aug 12, 6:45AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB), (the "Company"
announced that its French subsidiary, TFChem, has received confirmation for funding of CDN$1.2 million from Bpifrance (the French Public Investment Bank) and the district of Haute Normandie in the form of a no-interest loan. The funds will be used to advance the organization's anti-aging project. Sirona Biochem Announces Successful Synthesis of Anti-Inflammatory Compound for Bloom Burton & Co. Joint Venture
Marketwire - Thu Jul 31, 6:45AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB), (the "Company"
announces the achievement of the first batch of compound in the joint venture with Bloom Burton & Co. ("Bloom Burton" Compounds developed within the framework of the JV will be entering development in the areas of rare inflammatory and infectious diseases. Sirona Arranges Convertible Loans
Marketwire - Tue Jul 29, 4:48PM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB), (the "Company"
announces that is has entered into convertible loan agreements with arm's length parties (the "Lenders" for the purposes of renewing current outstanding loans in the total amount of $670,000. The original loans were taken out in late 2012 and became due this quarter. Sirona Biochem Announces Successful Completion of Two First Line Studies by Wanbang Biopharmaceuticals
Marketwire - Wed Jul 23, 6:45AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM)(OTCQX: SRBCF)(FRANKFURT: ZSB) (the "Company"
today announced that Wanbang Biopharmaceuticals has completed two pre-clinical efficacy studies of its SGLT2 inhibitor SBM-TFC-039. The studies independently confirm that SBM-TFC-039 increased Urinary Glucose Excretion and improved Oral Glucose Tolerance in normal SD rats. The results were consistent with those previously completed by Sirona Biochem. Sirona Announces Shares for Services Agreement
Marketwire - Tue Jul 22, 11:27AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB), (the "Company"
is pleased to announce that it has entered into a business consulting agreement (the "Agreement" with PRC Partners Ltd. of Hong Kong ("PRC" , for a six month term commencing July 15, 2014. Sirona Biochem Corporation - CEO Letter to Shareholders
Marketwire - Mon Jul 21, 9:27AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB) today provided a business update.
Sirona Announces Resignation of Neil Belenkie
Marketwire - Mon Jun 23, 4:00PM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB) (the "Company"
announces that Neil Belenkie has resigned as Chief Executive Officer of the Company. Neil has agreed to stay on with the company to assist in the transition until July 18, 2014. The Company thanks Mr. Belenkie for his hard work over the past 2 years and wishes him well in his future endeavors. Sirona Biochem Announces Patent for Anti-Aging Family of Compounds
Marketwire - Tue Apr 01, 6:45AM CDT
Sirona Biochem Corp. (TSX VENTURE: SBM.V) (OTCQX: SRBCF) (FRANKFURT: ZSB) is pleased to announce that a new patent application has been deposited by its subsidiary TFChem for a second generation of glycoprotein compounds. The first target marketplace for this technology will be anti-aging cosmetics. Future applications may include consumer packaged goods and prescription pharmaceuticals.
